Studies on the safety and immunogenicity of SARS-CoV- 2 vaccination in patients with inflammatory rheumatic diseases have so far not included mixed cryoglobulinaemia (MC) vasculitis.1–3 We report a prospective observational multicentre study on this disorder.
Visentini, M., Gragnani, L., Santini, S. A., Urraro, T., Villa, A., Monti, M., Palladino, A., Petraccia, L., La Gualana, F., Lorini, S., Marri, S., Madia, F., Stefanini, L., Basili, S., Fiorilli, M., Ferri, C., Zignego, A. L., Casato, M., Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2, <<ANNALS OF THE RHEUMATIC DISEASES>>, 2022; 81 (3): 441-443. [doi:10.1136/annrheumdis-2021-221248] [https://hdl.handle.net/10807/238936]
Flares of mixed cryoglobulinaemia vasculitis after vaccination against SARS-CoV-2
Santini, Stefano AngeloMethodology
;
2022
Abstract
Studies on the safety and immunogenicity of SARS-CoV- 2 vaccination in patients with inflammatory rheumatic diseases have so far not included mixed cryoglobulinaemia (MC) vasculitis.1–3 We report a prospective observational multicentre study on this disorder.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
